KR20230119676A - 클래스 ii 심부전 환자의 진행성 심부전 치료 방법 - Google Patents

클래스 ii 심부전 환자의 진행성 심부전 치료 방법 Download PDF

Info

Publication number
KR20230119676A
KR20230119676A KR1020237023192A KR20237023192A KR20230119676A KR 20230119676 A KR20230119676 A KR 20230119676A KR 1020237023192 A KR1020237023192 A KR 1020237023192A KR 20237023192 A KR20237023192 A KR 20237023192A KR 20230119676 A KR20230119676 A KR 20230119676A
Authority
KR
South Korea
Prior art keywords
subject
cells
heart failure
composition
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237023192A
Other languages
English (en)
Korean (ko)
Inventor
실비우 이떼스쿠
케네스 보로우
잭 헤이즈
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904675A external-priority patent/AU2020904675A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Publication of KR20230119676A publication Critical patent/KR20230119676A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237023192A 2020-12-15 2021-12-15 클래스 ii 심부전 환자의 진행성 심부전 치료 방법 Pending KR20230119676A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
AU2020904675A AU2020904675A0 (en) 2020-12-15 Method of treating progressive heart failure in subjects with Class II heart failure
AU2020904675 2020-12-15
AU2021900059 2021-01-12
AU2021900059A AU2021900059A0 (en) 2021-01-12 Method of treating progressive heart failure in subjects with Class II heart failure
AU2021902941 2021-09-10
AU2021902941A AU2021902941A0 (en) 2021-09-10 Method of treating progressive heart failure in subjects with Class II heart failure
AU2021903365A AU2021903365A0 (en) 2021-10-20 Method of treating progressive heart failure in subjects with Class II heart failure
AU2021903365 2021-10-20
US202163289868P 2021-12-15 2021-12-15
PCT/US2021/063645 WO2022132986A2 (en) 2020-12-15 2021-12-15 Method of treating progressive heart failure in subjects with class ii heart failure
US63/289,868 2021-12-15

Publications (1)

Publication Number Publication Date
KR20230119676A true KR20230119676A (ko) 2023-08-16

Family

ID=79686821

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023192A Pending KR20230119676A (ko) 2020-12-15 2021-12-15 클래스 ii 심부전 환자의 진행성 심부전 치료 방법

Country Status (6)

Country Link
US (1) US20240041934A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024500698A (cg-RX-API-DMAC7.html)
KR (1) KR20230119676A (cg-RX-API-DMAC7.html)
AU (1) AU2021403025A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202153A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022132986A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US9205112B2 (en) * 2007-04-23 2015-12-08 Creative Medical Health, Inc. Combination treatment of cardiovascular disease
CN107206027A (zh) * 2014-12-23 2017-09-26 迈索布拉斯特国际有限公司 进行性心力衰竭的预防
US20190224240A1 (en) * 2016-01-11 2019-07-25 Cardiocell, Llc Cell therapy for the treatment of non-ischemic heart failure

Also Published As

Publication number Publication date
WO2022132986A2 (en) 2022-06-23
AU2021403025A1 (en) 2023-07-20
WO2022132986A3 (en) 2022-07-28
US20240041934A1 (en) 2024-02-08
CA3202153A1 (en) 2022-06-23
JP2024500698A (ja) 2024-01-10

Similar Documents

Publication Publication Date Title
US20240041934A1 (en) Method of treating progressive heart failure in subjects with class ii heart failure
US20230124294A1 (en) Prevention of progressive heart failure
US20240197787A1 (en) Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
KR20220143092A (ko) 만성 이식편 대 숙주 질환의 치료 방법
CN116057173A (zh) 包括间充质前体细胞或干细胞的组合物及其用途
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) Method of treating severe graft versus host disease
US20250090589A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes
JP2025540288A (ja) 細胞組成物を用いた炎症治療方法
KR20250116745A (ko) 지속적인 염증을 가진 대상체에서 심부전을 치료하는 방법
EP4433070A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes
CN116829162A (zh) 治疗患有ii级心力衰竭的受试者的进行性心力衰竭的方法
EP4264275A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure
CN121985953A (zh) 用于治疗GvHD的三线治疗
CN117715649A (zh) 使用间充质谱系前体细胞或干细胞治疗特定患者的急性呼吸窘迫综合征(ards)的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230707

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241213

Comment text: Request for Examination of Application